Center-Authored Papers

Filters: Author is Wozniak, Antoinette J  [Clear All Filters]
Journal Article
Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ et al..  2006.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(19):3187-205. Abstract
West HL, Moon J, Wozniak AJ, Mack P, Hirsch FR, Bury MJ, Kwong M, Nguyen DD, Moore DF, Miao J et al..  2017.  Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials.. Clinical lung cancer. Abstract
Garland LL, Chansky K, Wozniak AJ, Tsao AS, Gadgeel SM, Verschraegen CF, Dasilva MA, Redman MW, Gandara DR.  2011.  Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 6(11):1938-45. Abstract
Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL et al..  2015.  Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(28):3199-3212. Abstract
Hesketh PJ, Chansky K, Wozniak AJ, Hirsch FR, Spreafico A, Moon J, Mack PC, Marchello BT, Franklin WA, Crowley J et al..  2008.  Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 3(9):1026-31. Abstract